story of the week
Outcomes With Nivolumab Plus Ipilimumab in Active Melanoma Brain Metastases
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study
Lancet Oncol 2021 Nov 10;N/A(N/A)1-13, HA Tawbi, PA Forsyth, FS Hodi, AP Algazi, O Hamid, CD Lao, SJ Moschos, MB Atkins, K Lewis, MA Postow, RP Thomas, J Glaspy, S Jang, NI Khushalani, AC Pavlick, MS Ernstoff, DA Reardon, R Kudchadkar, A Tarhini, C Chung, C Ritchings, P Durani, M Askelson, I Puzanov, KA MargolinFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.